Patents for Our Five Top Selling Products1
This disclosure is intended to simplify the activity of locating our patents documenting the scientific breakthroughs that these products represent. The patent table below lists patents currently in force that appear on the product virtual label, are cited in the 2022 10-K report, are cited in the Orange Book, and/or are cited in the Purple Book for our five top selling products1:
Product Proprietary/(Proper) Name |
Patent Number |
General Subject Matter |
1. Enbrel® (etanercept) |
U.S. 11,491,223; |
Formulations and methods of preparing formulations |
U.S. 8,063,182 |
Fusion protein and pharmaceutical compositions |
|
U.S. 8,163,522 |
DNA encoding fusion protein and methods of making fusion protein |
|
2. Prolia® (denosumab)*
|
U.S. 7,364,736 |
RANKL antibodies, including sequences |
U.S. 7,427,659 |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
|
U.S. 7,928,205 |
Methods for refolding of recombinant antibodies |
|
U.S. 8,058,418 |
Nucleic acids encoding RANKL antibodies and methods of producing RANKL antibodies |
|
U.S. 9,012,178 |
Methods of culturing mammalian cells to express protein in a serum free medium |
|
U.S. 9,133,493 |
Methods of culturing mammalian cells |
|
U.S. 9,228,168 |
Methods of stabilizing feed media |
|
U.S. 9,320,816 |
Methods of treating cell culture media |
|
U.S. 9,328,134 |
Methods of making proteins with modified glycosylation profile |
|
U.S. 9,359,435 |
Methods of modulating glycoform content |
|
U.S. 9,388,447 |
Independent tyrosine feed |
|
U.S. 9,481,901 |
Methods of influencing high mannose glycoform content |
|
U.S. 10,167,492 |
Methods of influencing fucosylated glycan content |
|
U.S. 10,513,723 |
Methods of influencing high mannose glycoform content |
|
U.S. 10,583,397 |
Systems and methods to control filtration |
|
U.S. 10,822,630 |
Methods of influencing fucosylated glycan content |
|
U.S. 10,894,972 |
Methods of influencing high mannose glycoform content |
|
U.S. 11,077,404 |
Systems and methods to control filtration |
|
U.S. 11,098,079 |
Methods of using a charged depth filter |
|
U.S. 11,130,980 |
Methods of regulating high mannose glycoform content |
|
U.S. 11,254,963 |
Methods of influencing high mannose glycoform content |
|
U.S. 11,299,760 |
Methods of regulating high mannose glycoform content |
|
U.S. 11,434,514 |
Methods of influencing high mannose glycoform content |
|
U.S. 11,459,595 |
Methods for increasing mannose content of recombinant proteins |
|
EP 1 409 016 |
RANKL antibodies, including sequences |
|
4. Otezla® (apremilast) |
U.S. 7,427,638 |
Composition and compound |
U.S. 7,893,101 |
Crystalline form |
|
U.S. 9,872,854; |
Methods of treatment |
|
EP 2 962 690 |
Compositions, compounds and methods of treatment |
|
5. Aranesp® (darbepoetin alfa) |
U.S. 7,217,689 |
Glycosylation analogs of erythropoietin proteins |
*Prolia and XGEVA are brand names for denosumab, but differ in indications.
1. Based on our publicly reported sales as disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 9, 2023. We are providing this information as of September 1, 2023.